Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 85

Similar articles for PubMed (Select 25075204)

1.

Automated quantitative multiplex immunofluorescence in situ imaging identifies phospho-S6 and phospho-PRAS40 as predictive protein biomarkers for prostate cancer lethality.

Shipitsin M, Small C, Giladi E, Siddiqui S, Choudhury S, Hussain S, Huang YE, Chang H, Rimm DL, Berman DM, Nifong TP, Blume-Jensen P.

Proteome Sci. 2014 Jul 12;12:40. doi: 10.1186/1477-5956-12-40. eCollection 2014.

2.

Pathway-based identification of biomarkers for targeted therapeutics: personalized oncology with PI3K pathway inhibitors.

Andersen JN, Sathyanarayanan S, Di Bacco A, Chi A, Zhang T, Chen AH, Dolinski B, Kraus M, Roberts B, Arthur W, Klinghoffer RA, Gargano D, Li L, Feldman I, Lynch B, Rush J, Hendrickson RC, Blume-Jensen P, Paweletz CP.

Sci Transl Med. 2010 Aug 4;2(43):43ra55. doi: 10.1126/scitranslmed.3001065.

3.

Heterogeneity mapping of protein expression in tumors using quantitative immunofluorescence.

Faratian D, Christiansen J, Gustavson M, Jones C, Scott C, Um I, Harrison DJ.

J Vis Exp. 2011 Oct 25;(56):e3334. doi: 10.3791/3334.

4.

Predicting high-risk disease using tissue biomarkers.

Donovan MJ, Cordon-Cardo C.

Curr Opin Urol. 2013 May;23(3):245-51. doi: 10.1097/MOU.0b013e32835f89cc. Review.

PMID:
23478499
6.

Zinc α2-glycoprotein as a potential novel urine biomarker for the early diagnosis of prostate cancer.

Katafigiotis I, Tyritzis SI, Stravodimos KG, Alamanis C, Pavlakis K, Vlahou A, Makridakis M, Katafigioti A, Garbis SD, Constantinides CA.

BJU Int. 2012 Dec;110(11 Pt B):E688-93. doi: 10.1111/j.1464-410X.2012.11501.x. Epub 2012 Sep 28.

PMID:
23020913
7.

A robust tool for discriminative analysis and feature selection in paired samples impacts the identification of the genes essential for reprogramming lung tissue to adenocarcinoma.

Toh SH, Prathipati P, Motakis E, Kwoh CK, Yenamandra SP, Kuznetsov VA.

BMC Genomics. 2011 Nov 30;12 Suppl 3:S24. doi: 10.1186/1471-2164-12-S3-S24. Epub 2011 Nov 30.

8.

Protein expression of PTEN, insulin-like growth factor I receptor (IGF-IR), and lethal prostate cancer: a prospective study.

Zu K, Martin NE, Fiorentino M, Flavin R, Lis RT, Sinnott JA, Finn S, Penney KL, Ma J, Fazli L, Gleave ME, Bismar TA, Stampfer MJ, Pollak MN, Loda M, Mucci LA, Giovannucci E.

Cancer Epidemiol Biomarkers Prev. 2013 Nov;22(11):1984-93. doi: 10.1158/1055-9965.EPI-13-0349. Epub 2013 Aug 27.

9.

High phospho-Stathmin(Serine38) expression identifies aggressive endometrial cancer and suggests an association with PI3K inhibition.

Wik E, Birkeland E, Trovik J, Werner HM, Hoivik EA, Mjos S, Krakstad C, Kusonmano K, Mauland K, Stefansson IM, Holst F, Petersen K, Oyan AM, Simon R, Kalland KH, Ricketts W, Akslen LA, Salvesen HB.

Clin Cancer Res. 2013 May 1;19(9):2331-41. doi: 10.1158/1078-0432.CCR-12-3413. Epub 2013 Mar 28.

10.

An immunohistochemical signature comprising PTEN, MYC, and Ki67 predicts progression in prostate cancer patients receiving adjuvant docetaxel after prostatectomy.

Antonarakis ES, Keizman D, Zhang Z, Gurel B, Lotan TL, Hicks JL, Fedor HL, Carducci MA, De Marzo AM, Eisenberger MA.

Cancer. 2012 Dec 15;118(24):6063-71. doi: 10.1002/cncr.27689. Epub 2012 Jun 6.

11.

Use of classical and novel biomarkers as prognostic risk factors for localised prostate cancer: a systematic review.

Sutcliffe P, Hummel S, Simpson E, Young T, Rees A, Wilkinson A, Hamdy F, Clarke N, Staffurth J.

Health Technol Assess. 2009 Jan;13(5):iii, xi-xiii 1-219. doi: 10.3310/hta13050. Review.

12.

A systems-based modelling approach using transurethral resection of the prostate (TURP) specimens yielded incremental prognostic significance to Gleason when predicting long-term outcome in men with localized prostate cancer.

Donovan MJ, Khan FM, Bayer-Zubek V, Powell D, Costa J, Cordon-Cardo C.

BJU Int. 2012 Jan;109(2):207-13. doi: 10.1111/j.1464-410X.2011.10316.x. Epub 2011 Jul 6.

PMID:
21733075
13.

Development of a robust flow cytometry-based pharmacodynamic assay to detect phospho-protein signals for phosphatidylinositol 3-kinase inhibitors in multiple myeloma.

Li C, Takahashi C, Zhang L, Huseni M, Stankovich B, Mashhedi H, Lee J, French D, Anderson JE, Kim D, Howell K, Brauer MJ, Kowanetz M, Yan Y, Humke E, Ebens A, Hampton G, Lackner MR, Hegde P, Jia S.

J Transl Med. 2013 Mar 23;11:76. doi: 10.1186/1479-5876-11-76.

14.

PTEN promoter methylation and activation of the PI3K/Akt/mTOR pathway in pediatric gliomas and influence on clinical outcome.

Mueller S, Phillips J, Onar-Thomas A, Romero E, Zheng S, Wiencke JK, McBride SM, Cowdrey C, Prados MD, Weiss WA, Berger MS, Gupta N, Haas-Kogan DA.

Neuro Oncol. 2012 Sep;14(9):1146-52. doi: 10.1093/neuonc/nos140. Epub 2012 Jun 29.

15.

Genomic Predictors of Outcome in Prostate Cancer.

Boström PJ, Bjartell AS, Catto JW, Eggener SE, Lilja H, Loeb S, Schalken J, Schlomm T, Cooperberg MR.

Eur Urol. 2015 Apr 23. pii: S0302-2838(15)00310-3. doi: 10.1016/j.eururo.2015.04.008. [Epub ahead of print] Review.

PMID:
25913390
16.

Novel prognostic markers in the serum of patients with castration-resistant prostate cancer derived from quantitative analysis of the pten conditional knockout mouse proteome.

Kälin M, Cima I, Schiess R, Fankhauser N, Powles T, Wild P, Templeton A, Cerny T, Aebersold R, Krek W, Gillessen S.

Eur Urol. 2011 Dec;60(6):1235-43. doi: 10.1016/j.eururo.2011.06.038. Epub 2011 Jun 29.

PMID:
21741162
17.

Activation of PI3K/mTOR pathway occurs in most adult low-grade gliomas and predicts patient survival.

McBride SM, Perez DA, Polley MY, Vandenberg SR, Smith JS, Zheng S, Lamborn KR, Wiencke JK, Chang SM, Prados MD, Berger MS, Stokoe D, Haas-Kogan DA.

J Neurooncol. 2010 Mar;97(1):33-40. doi: 10.1007/s11060-009-0004-4. Epub 2009 Aug 25.

18.

Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer.

Leyten GH, Hessels D, Jannink SA, Smit FP, de Jong H, Cornel EB, de Reijke TM, Vergunst H, Kil P, Knipscheer BC, van Oort IM, Mulders PF, Hulsbergen-van de Kaa CA, Schalken JA.

Eur Urol. 2014 Mar;65(3):534-42. doi: 10.1016/j.eururo.2012.11.014. Epub 2012 Nov 15.

PMID:
23201468
19.

Evaluation of protein biomarkers of prostate cancer aggressiveness.

Rizzardi AE, Rosener NK, Koopmeiners JS, Isaksson Vogel R, Metzger GJ, Forster CL, Marston LO, Tiffany JR, McCarthy JB, Turley EA, Warlick CA, Henriksen JC, Schmechel SC.

BMC Cancer. 2014 Apr 5;14:244. doi: 10.1186/1471-2407-14-244.

20.

Testing a multigene signature of prostate cancer death in the Swedish Watchful Waiting Cohort.

Mucci LA, Pawitan Y, Demichelis F, Fall K, Stark JR, Adami HO, Andersson SO, Andrén O, Eisenstein A, Holmberg L, Huang W, Kantoff PW, Kim R, Perner S, Stampfer MJ, Johansson JE, Rubin MA.

Cancer Epidemiol Biomarkers Prev. 2008 Jul;17(7):1682-8. doi: 10.1158/1055-9965.EPI-08-0044. Epub 2008 Jun 26.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk